(NASDAQ:IZEA), $8.8 Million Year-Over-Year Improvement in Net ResultsPositive Cash from Operations ORLANDO, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Creator Economy solutions for marketers, reported its financial and operational results for the third quarter ended September 30, 2025. Q3 2025 Financial Summary Compared […]

(NASDAQ:LINK), Revenue Up 11% Year-over-Year, Marking Second Consecutive Quarter of Double-Digit GrowthBuilding Momentum for 2026 Through Continued Organic Growth and Strengthened M&A Pipeline FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Interlink Electronics, Inc. (Nasdaq: LINK) (“Interlink” or the “Company”), a global leader in sensor technology and printed electronic solutions, today reported results for the

(NasdaqGM:USIO), Revenue up over $1 million sequentially from Second Quarter 2025 Total payment dollars processed through all payment channels up 8% versus the prior year period Sequential increase across all processing metrics for all divisions All-time quarterly records for all ACH processing metrics, Credit Card volume, and PINless Debit volume and transactions SAN ANTONIO, Nov.

(NASDAQ:LYRA), – Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the

(NasdaqGM:PCYO), DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) — Pure Cycle Corporation (NASDAQ Capital Market: PCYO) announced its financial results for the year ended August 31, 2025. Pure Cycle reported $13.1 million of net income for the year ended August 31, 2025, which is a 13% increase in net income from 2024 and marks our eighth

(NASDAQ:CELC), Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Presented updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa(R)

(NASDAQ:AENT), Revenue up 11% to $254M, driven by strength in physical media and collectibles Adjusted EBITDA up 259% to $12.2M; Gross Margin expands 340 basis points to 14.6% Net Income increased to $4.9M, or $0.10 per share, compared to $0.4M in Q1 FY25 AI Implementation delivering early productivity gains across sales and operations Strengthened balance

(NASDAQ:IBIO), Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity SAN DIEGO,

(NASDAQ:CLBT),(NASDAQ:CLBTW), ARR grew 19% to $439.8 million; Revenue grew 18% to $126.0 million Net income of $20.2 million supports non-GAAP net income of $36.9 million and adjusted EBITDA of $37.7 million, 29.9% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress GlobeNewswire November 12, 2025 Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while